Logo

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com

Last Updated: 21.06.2025 07:12

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com

RAHWAY, N.J.--(BUSINESS WIRE)--

June 9, 2025 3:11 pm ET

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has ap… [+11553 chars]

How scientists confirmed the existence of 200-million-year-old species thought to be extinct - ABC News